QUOTE AND NEWS
Jutia Group  May 12  Comment 
[PR Newswire] - INDIANAPOLIS, May 12, 2015 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that it has commenced a cash tender offer for up to $1.6 billion aggregate principal amount (the "tender cap") of specified series of its...
FierceBiotech  May 12  Comment 
Eli Lilly has turned to Germany's BioNTech to form its latest collaboration on the cancer immunotherapy front, handing over $60 million--$30 million as a signing bonus and $30 million for equity--and promising up to $300 million in milestones for...
GenEng News  May 11  Comment 
Eli Lilly and BioNTech said today they have launched a research collaboration to discover new cancer immunotherapies, in a deal that could generate more than $360 million for the German biotech. The companies said they will partner to identify...
Jutia Group  May 11  Comment 
[PR Newswire] - INDIANAPOLIS and MAINZ, Germany, May 11, 2015 /PRNewswire/ -- Eli Lilly and Company (LLY) and BioNTech AG today announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will...
Forbes  May 11  Comment 
Tomorrow we will publish an in-depth interview with Eli Lilly and Company’s President of Emerging Markets Chito Zulueta on the company’s strategies as it enters new markets and how it can approve clinical development in these...
GenEng News  May 8  Comment 
Transition Therapeutics said today it has exclusively licensed—through a wholly owned Irish subsidiary—rights to develop and commercialize Eli Lilly’s small-molecule muscle drug candidate TT701 from the pharma giant for up to $100...
Jutia Group  May 4  Comment 
[PR Newswire] - INDIANAPOLIS, May 4, 2015 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2015 of $0.50 per share on outstanding common stock. ... Read more on this. ...
Jutia Group  May 1  Comment 
[PR Newswire] - INDIANAPOLIS, May 1, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015. Derica Rice, Lilly's executive ... Read more on this....
TheStreet.com  Apr 29  Comment 
NEW YORK (TheStreet) -- Shares of Eli Lilly and Co  are up 1.49% to $72.24 in mid-morning trading Tuesday, after the pharmaceutical company had its rating raised to "buy" from "neutral" by analysts at Citigroup this morning. The firm also...
Benzinga  Apr 28  Comment 
In a report published Tuesday, BofA Merrill Lynch analysts maintained a Neutral rating on Eli Lilly and Co (NASDAQ: LLY), with a price objective of $74, saying that there were several catalysts "on the horizon" for the company. Eli Lilly...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki